Dried Blood Spot Collection Cards Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Dried Blood Spot Collection Cards Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Dried Blood Spot Collection Cards Market is expected to witness a CAGR of 3% during the forecast period.

COVID-19 has impacted the market growth. The increasing burden of COVID-19 cases among the population has increased the demand for early detection of the disease which increase the usage of dried blood spot collection cards. For instance, according to an article published in March 2021, titled ‘Use of dried blood spot samples for SARS-CoV-2 antibody detection using the Roche Elecsys high throughput immunoassay’, it has been observed that the dried blood spot method showed a sensitivity and specificity of 89% and 100% respectively, as compared with using plasma. In addition, as per the same source, dried blood spot offers a new way of identifying unreported COVID-19 cases (i.e., asymptomatic infections), which may be useful in creating specialized vaccination regimens and comprehending the pandemic's overall burden and case count. Thus, COVID-19 has significantly impacted the market growth.

Certain factors that are propelling the market growth are the increasing use of dried blood spot collection cards in diagnostic testing and the rise in forensic toxicology applications. For instance, according to the 2022 data published by the Centers for Disease Control and Prevention (CDC), newborn screening identifies conditions that can affect a child’s long-term health or survival. Early detection, diagnosis, and intervention can prevent death or disability, and enable children to reach their full potential. In addition, as per the same source, the CDC's 'Newborn Screening and Molecular Biology Branch' support newborn screening programs that help in increasing awareness among the population regarding newborn conditions and the importance of screening. Such initiatives are likely to increase the demand for newborn screening tests which in turn is anticipated to propel the demand for dried blood collection cards thereby boosting the market growth.

Additionally, according to 2022 statistics published by HIV.gov, about 38.4 million people were living with HIV in 2020 around the world, of which 36.7 million were adults and 1.7 million were children (15 years and above). In addition, as per the same source, around 650,000 people died from AIDS-related illnesses in 2021 as compared to 1.4 million in 2010. Thus, the increasing burden of HIV disease among the population is expected to propel the demand for early diagnosis of the condition which is anticipated to increase the demand for dried blood spot collection cards, thereby fueling the market growth. Similarly, as per an article published in March 2020, titled ‘Dried Blood Spot Tests for the Diagnosis and Therapeutic Monitoring of HIV and Viral Hepatitis B and C’, it has been observed that the dried blood spot method used for the detection of anti-HIV and anti-HCV on western blot shows 98% sensitivity. Due to the significant rise in HIV incidence, key market companies are now providing sophisticated dried blood spot collection cards that facilitate quick HIV diagnosis which is expected to positively impact the market growth. For instance, as per an article published in October 2021, titled 'HIV-1 diagnosis using dried blood spots from patients in Kinshaa, DRC: a tool to detect misdiagnosis and achieve World Health Organization 2030 targets', it has been observed that Elecsys HIV combi PT and VIDAS HIV Duo Quick immunoassays showed high sensitivity and specificity with dried blood spot collection card method and in sub-Saharan Africa, RDT-based serological diagnosis might result in HIV misdiagnosis, which can have personal and social repercussions. This is expected to increase the adoption of dried blood spot collection cards for diagnosing HIV, thereby propelling market growth.

However, the contamination caused by dried blood spot collection cards is expected to restrain the market growth over the forecast period.

Key Market TrendsNewborn Screening Segment Expects to Register a High CAGR Over the Forecast Period

The factors attributing to the segment growth are an increasing number of newborn babies and growing demand for newborn screening.

Newborn screening is a set of laboratory tests performed on newborn babies to detect a set of known genetic diseases. This testing is performed on a blood sample obtained from a heel prick when the baby is two or three days old.

For instance, in developed countries such as the United States, newborn screening is mandatory for a defined set of genetic diseases, although the exact set differs from state to state. Newborn screening tests focus on conditions for which early diagnosis is important to treating or preventing disease. Early detection of those conditions allows different kinds of treatments and interventions to be provided very early in a newborn's life when it can really make a difference in health outcomes and even help to prevent severe, irreversible disability.

In addition, the Study “Need and Viability of Newborn Screening Programme in India: Report from a Pilot Study” published in March 2022, stated that the financial loss for India due to these preventable diseases is much higher than the overall expenditure for screening, diagnosis, and treatment. Therefore, this cost-effective analysis justifies the need for a national newborn screening program in India. Hence, the increasing demand for newborn screening across the globe is expected to drive the demand for dried blood spot collection cards, thereby propelling segment growth.

Furthermore, the growing launch of newborn screening services, increasing research and development activities, and rising adoption of key strategies are also contributing to the market growth. For instance, in March 2022, Oxford University initiated a population-based newborn screening study in the Thames Valley. This study aims to make it possible to detect spinal muscular atrophy within days of birth before symptoms develop so that any affected newborn can receive diagnosis and treatment at the earliest possible opportunity.

Thus, owing to the aforementioned factors, the market is expected to grow significantly during the forecast period.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a significant share in the dried blood spot collection cards market over the forecast period owing to the factors such as the high demand for newborn screening, and the rising prevalence of HIV diseases. In addition, the growing technological advancements, the presence of several major players, rising healthcare expenditure, the presence of well-established healthcare infrastructure, and increasing research and development expenditure are also expected to boost the market growth over the forecast period.

With the increasing pharmaceutical spending on research and development, adoption of various business strategies, and advanced technology, downstream processing is being increasingly adopted in the biopharmaceutical industry, boosting market growth over the forecast period. For instance, according to the 2022 data published by the Organization for Economic Cooperation and Development (OECD), the United States, Canada, and Mexico spent USD 0.66, USD 0.03, and USD 0.01 million on research and development activities, respectively. Thus, the high investment in research and development by the companies further increases the capabilities of the company to adopt innovative technologies, thereby supporting the market growth.

In addition, according to an article published in July 2022, titled ‘The Progress and Future of US Newborn Screening’, there were 109 late-stage gene-targeted therapies, as of February 2021 and it is expected that Food and Drug Administration will approve 10–20 cell and gene therapies per year by 2025. Thus, the increasing approvals of different therapies are expected to increase the company’s activities in developing effective drugs and treatment options for newborn screening.

The increasing number of birth defects in children and associated risks of mortality raises the need for newborn screening to reduce the number of mortality cases. For instance, a study titled “Association of Birth Defects with Child Mortality Before Age 14 Years” published in April 2022, conducted in Canada from April 2006 to March 2020 studied the mortality rates by cause of death in children with and without birth defect. It found that birth defects were strongly associated with mortality owing to circulatory, respiratory, and digestive causes and the finding raises the possibility that the role of birth abnormalities in mortality numbers may be understated. It also stated that birth defects such as heart problems, chromosomal anomalies, and central nervous system disorders all increased the chance of death by more than 10 times, 8 times, and 7 times, respectively, and the risk of death was significantly higher between days 28 and 364 of life, however, it was also higher at other times. Hence, the demand for newborn screening in the region is expected to increase over time and the market is expected to grow in the region.

Thus, owing to the aforementioned factors, the market is expected to grow significantly during the forecast period.

Competitive Landscape

The dried blood spot collection cards market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are F. Hoffmann-La Roche Ltd, QIAGEN, Shimadzu Scientific Instruments, Eastern Business Forms, Inc, Ahlstrom-Munksjö , PerkinElmer, ARCHIMEDlife, and CENTOGENE N.V.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.